{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:52:08Z","timestamp":1761709928745},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,8]]},"DOI":"10.7759\/cureus.22021","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T15:00:30Z","timestamp":1644332430000},"source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and Management of Metabolic Syndrome in Adult Psychiatric Patients Receiving Second-Generation Antipsychotics at Sheikh Khalifa Medical City"],"prefix":"10.7759","author":[{"given":"Wadha","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waeil","family":"Al Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"United Arab Emirates population. (2019). https.\/\/www.worldometers.info\/world-population\/united-arab-emirates-population\/."},{"key":"ref2","unstructured":"Psychology and Mental Health Services in the United Arab Emirates. (2015). Accessed. June 2019: https:\/\/www.apa.org\/international\/pi\/2015\/06\/psychology-arab."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1213-6","article-title":"Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications","volume":"17","author":"Llorca PM","year":"2017","unstructured":"Llorca PM, Lan\u00e7on C, Hartry A, Brown TM, DiBenedetti DB, Kamat SA, Fran\u00e7ois C. Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications. BMC Psychiatry. 2017, 17:67. 10.1186\/s12888-017-1213-6","journal-title":"BMC Psychiatry"},{"key":"ref4","unstructured":"What is metabolic syndrome? NIH. (2016). Accessed. November 12, 2017: https:\/\/www.nhlbi.nih.gov\/health-topics\/metabolic-syndrome."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"DE Hert M","year":"2009","unstructured":"DE Hert M, Schreurs V, Vancampfort D, VA Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009, 8:15-22. 10.1002\/j.2051-5545.2009.tb00199.x","journal-title":"World Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol","volume":"57","author":"Purdon SE","year":"2000","unstructured":"Purdon SE, Jones BD, Stip E, et al.. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry. 2000, 57:249-58. 10.1001\/archpsyc.57.3.249","journal-title":"Arch Gen Psychiatry"},{"key":"ref7","article-title":"Atypical Antipsychotic Agents","author":"Vasan S","year":"2017","unstructured":"Vasan S, Abdijadid S. Atypical Antipsychotic Agents. StatPearls [Internet], Treasure Island (FL); 2017."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.322.8794","article-title":"Quality of life for chronic psychiatric illnesses and home care","volume":"32","author":"Molu NG","year":"2016","unstructured":"Molu NG, Ozkan B, Icel S. Quality of life for chronic psychiatric illnesses and home care. Pak J Med Sci. 2016, 32:511-5. 10.12669\/pjms.322.8794","journal-title":"Pak J Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2007.01095.x","article-title":"Physical illness and schizophrenia: a review of the literature","author":"Leucht S","year":"2007","unstructured":"Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007, 116:317-33. Accessed: Retrieved November 2018, from PubMed: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17919153. 10.1111\/j.1600-0447.2007.01095.x"},{"key":"ref10","unstructured":"WHO. Schizophrenia. (2022). http.\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha S","year":"2007","unstructured":"Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007, 64:1123-31. 10.1001\/archpsyc.64.10.1123","journal-title":"Arch Gen Psychiatry"},{"key":"ref12","article-title":"Metabolic Syndrome and Psychiatric Illness: Interactions, Pathophysiology, Assessment, and Treatment","author":"Mendelson S","year":"2018","unstructured":"Mendelson S. Metabolic Syndrome and Psychiatric Illness: Interactions, Pathophysiology, Assessment, and Treatment. Academic Press, London; 2018."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111408461","article-title":"Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis","volume":"26","author":"De Fruyt J","year":"2012","unstructured":"De Fruyt J, Deschepper E, Audenaert K, et al.. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012, 26:603-17. 10.1177\/0269881111408461","journal-title":"J Psychopharmacol"},{"key":"ref14","unstructured":"AHRQ. Comparative effectiveness of first and second generation antipsychotics in the adult population. (2010). Accessed. November 2018: https:\/\/effectivehealthcare.ahrq.gov\/products\/antipsychotics-adults\/research-protocol."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones PB","year":"2006","unstructured":"Jones PB, Barnes TR, Davies L, et al.. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006, 63:1079-87. 10.1001\/archpsyc.63.10.1079","journal-title":"Arch Gen Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/070674370404900504","article-title":"New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?","volume":"49","author":"Awad AG","year":"2004","unstructured":"Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?. Can J Psychiatry. 2004, 49:297-302. 10.1177\/070674370404900504","journal-title":"Can J Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis JM","year":"2003","unstructured":"Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003, 60:553-64. 10.1001\/archpsyc.60.6.553","journal-title":"Arch Gen Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19 Suppl 1","author":"Newcomer JW","year":"2005","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 19 Suppl 1:1-93. 10.2165\/00023210-200519001-00001","journal-title":"CNS Drugs"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.068","article-title":"Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss","volume":"53","author":"Lavie CJ","year":"2009","unstructured":"Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009, 53:1925-32. 10.1016\/j.jacc.2008.12.068","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with the","author":"Cooper SJ","year":"2016","unstructured":"Cooper SJ, Reynolds GP, Barnes TRE. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with the. J Psychopharmacol. 2016, 1-32. 10.1177\/0269881116645254","journal-title":"J Psychopharmacol"},{"key":"ref21","unstructured":"NICE. Type 2 diabetes. prevention in people at high risk. (2012). Accessed: September 2017: https:\/\/www.nice.org.uk\/guidance\/ph38\/resources\/type-2-diabetes-prevention-in-people-at-high-risk-pdf-1996304192197."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.03.17","article-title":"Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders","volume":"6","author":"Aronow WS","year":"2018","unstructured":"Aronow WS, Shamliyan TA. Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders. Ann Transl Med. 2018, 6:147. 10.21037\/atm.2018.03.17","journal-title":"Ann Transl Med"},{"key":"ref23","unstructured":"Guidance on the use of antipsychotics. NHS. (2019). Accessed. October 2015: http:\/\/www.sussexpartnership.nhs.uk\/sites\/default\/files\/documents\/antipsychotic_guidelines_version_3.2_-_oct_15_-_wit...."},{"key":"ref24","unstructured":"NHS. Guidelines for the management of QTc prolongation in adults prescribed antipsychotics. (2017). Accessed. June 2019: https:\/\/www.england.nhs.uk\/north\/wp-content\/uploads\/sites\/5\/2018\/12\/QTc-flow-diagram-with-medications-final-Dec-17-A3...."},{"key":"ref25","article-title":"Policy for Community Case Management Team and Crisis Management (D-BSP-MD-01-011)","author":"El Sabbahy M","year":"2017","unstructured":"El Sabbahy M. Policy for Community Case Management Team and Crisis Management (D-BSP-MD-01-011). Sheikh Khalifa Medical City, Behavioral Science Pavilion, Abu Dhabi; 2017."},{"key":"ref26","article-title":"The importance of the medical record: a critical professional responsibility","volume":"31","author":"Ngo E","year":"2016","unstructured":"Ngo E, Patel N, Chandrasekaran K, Tajik AJ, Paterick TE. The importance of the medical record: a critical professional responsibility. J Med Pract Manage. 2016, 31:305-8.","journal-title":"J Med Pract Manage"},{"key":"ref27","unstructured":"ZHO. (2018). Accessed. July 2018: https:\/\/zho.ae\/en\/ZHOProfile\/Pages\/AboutUs.aspx."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/80287-prevalence-and-management-of-metabolic-syndrome-in-adult-psychiatric-patients-receiving-second-generation-antipsychotics-at-sheikh-khalifa-medical-city","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:32Z","timestamp":1707507872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/80287-prevalence-and-management-of-metabolic-syndrome-in-adult-psychiatric-patients-receiving-second-generation-antipsychotics-at-sheikh-khalifa-medical-city"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.22021","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,8]]}}}